Skip to search formSkip to main contentSkip to account menu

24 HR Rotigotine 0.25 MG/HR Transdermal System

Known as: rotigotine 0.25 MG/HR 24 HR Transdermal Patch, rotigotine 6 MG/Day 24HR Transdermal System, ROTIGOTINE 6MG/24HRS PATCH 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Antiparkinson AgentsRotigotine Transdermal System
RotigotineTransdermal System

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
ยาแผ่นแปะ Rotigotine Rotigotine Transdermal Patch
บทคดยอ Rotigotine ชนดแผนแปะ เปนยาในกลม non-ergot dopamine agonists… 
2016
2016
Allergic contact dermatitis caused by rotigotine in a transdermal therapeutic system
Conflicts of interest: No conflict of interests. desquamation at the application sites of a rotigotine TTS (Neupro® 6 mg/24 h… 
2014
2014
One kind of rotigotine microemulsion and microemulsion gel
The present invention relates to a rotigotine microemulsion and microemulsion gel, it belongs to the field of pharmaceutical… 
2013
2013
Development of implants for sustained release of rotigotine to achieve CDS for the treatment of PD
SUMMARY Rotigotine was formulated as extendedrelease implants in this study to achieve CDS for the treatment of PD. The… 
Review
2008
Review
2008
Rotigotine Transdermal Patch
Abstract▴ Rotigotine is a non-ergolinic dopamine receptor agonist, formulated as a silicone-based transdermal patch, which has… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)